'Holding onto life': Ontario cystic fibrosis patients await access to life-saving drug just approved by Health Canada
After just one day as part of a trial for a genetic modulator medication for cystic fibrosis patients, Madi Vanstone knew it was working.
“Her quality of life was horrible,” Beth Vanstone, Madi’s mother, told CTV News Toronto Tuesday.
“I don't exaggerate when I say that she spent probably 90 per cent of her time on the couch with a blanket and just not feeling well. She missed 96 days of school in Grade 6.”
After just one day on the trial drug, Kalydeco, Madi could breathe through her nose — something she didn’t even know was possible until that day.
“She started to gain weight … her lung function went from 70 per cent to 115 per cent of expected value in just 30 days,” Vanstone said.
Madi performed so well on Kalydeco that in 2019 she was able to traverse the Great Wall of China with her mother, raising more than $30,000 for Cystic Fibrosis Canada.
“It was a tribute to her newfound health,” Vanstone said.
Beth and Madi Vanstone on the Great Wall of China (Provided by Beth Vanstone)
Cystic fibrosis is the most common fatal genetic disease in children and young adults in Canada. The disease impacts the patients’ digestive and respiratory systems until the lungs eventually stop working. It can be caused by over 2,000 different variations of genetic mutations, Vanstone said.
While life-changing for Madi, Kalydeco doesn’t work as efficiently for everyone with cystic fibrosis. In fact, it is only effective for three to four per cent of the cystic fibrosis community, as it targets only two per cent of genetic mutations causing CF.
A more effective, alternate genetic modulator, Trikafta, was introduced into the American market in 2019. Research shows that Trikafta impacts 90 per cent of the cystic fibrosis community, as opposed to Kalydeco’s three to four per cent.
“Trikafta is the golden goose. [It’s] hitting it out of the park. People have come off of life support and out of their hospital beds and are back to work,” Vanstone said.
Within 90 days of introduction, the U.S. Food and Drug Administration had Trikafta on the shelves, available to American CF patients to purchase, but that wasn’t the case in Canada.
Since Trikafta arrived on the U.S. market in 2019, the Vanstones, alongside many other families and patients, have been lobbying Health Canada to approve the drug.
“You have to think that in October 2019, [Trikafta] was in the hands of patients in the U.S. and we're in June 2021 and we're still waiting to get access,” Vanstone said.
“We had to lobby the federal government for like, a year, probably, in order to get them to let Trikafta to come in.”
On Friday, June 18, Health Canada announced its approval for Trikafta.
“We're celebrating huge, don't get me wrong, but we still have another step to get it into patients' hands, because right now, people are literally holding on to life in order to get this drug,” Vanstone said.
CEO and President of Cystic Fibrosis Canada, Kelly Grover, called the moment "a special day for [the cystic fibrosis] community."
“Together we have been fighting hard for access to these medications. Thousands of letters and signatures and hundreds of meetings later, we are finally seeing the progress our community deserves,” said Grover in a release on the announcement.
Ottawa’s announcement means doctors can now prescribe Trikafta to Canadian patients. Although, with the drug costing approximately $300,000 USD a year per patient, provincial governments now need to negotiate pricing with manufacturer Vertex before getting the drug onto shelves and into the hands of CF patients across the country.
“I’ve been proud to work alongside people like Beth and Madi Vanstone, and Sasha Haughian and Jamie Larocque, who have been tireless in their efforts to access these innovative drugs.” Simcoe-Grey MPP Jim Wilson said in a release.
“Much of the credit for this progress goes to families in our region who have fought long and hard for these life-saving drugs."
Wilson said the ball is “now in Doug Ford’s court.”
“I am confident the government of Ontario will live up to its promise to list these drugs on the Ontario Drug Benefit Formulary and quickly make them available to patients,” he said.
When reached for comment, the Ontario Ministry of Health said that Ontario is looking forward to "continuing existing discussions with Vertex."
"Ontario recognizes that the cystic fibrosis community is anxious for access to new and effective treatments such as Trikafta ... These steps are a vital part of the overall process to ensure that drug treatments entering the Canadian market are safe, effective and provide value," spokesperson Bill Campbell told CTV News Toronto Wednesday.
Vanstone hopes that provinces act quickly in recognizing the importance of getting Trikafta into patients' hands, adding that many are “holding onto life” in the meantime.
“The CF community has worked tirelessly for over 10 years to get to this point,” Vanstone said.Whe
“We hope that the provinces will recognize [our work] and add this drug to their formulary so that patients can put their shoulders down and live their best lives now. We deserve it.
CTVNews.ca Top Stories
Appeals court overturns Harvey Weinstein's 2020 rape conviction from landmark trial
New York’s highest court on Thursday overturned Harvey Weinstein’s 2020 rape conviction, finding the judge at the landmark #MeToo trial prejudiced the ex-movie mogul with improper rulings, including a decision to let women testify about allegations that weren’t part of the case.
BREAKING Honda to get up to $5B in govt help for EV battery, assembly plants
Honda is set to build an electric vehicle battery plant next to its Alliston, Ont., assembly plant, which it is retooling to produce fully electric vehicles, all part of a $15-billion project that is expected to include up to $5 billion in public money.
MPP Sarah Jama asked to leave Ontario legislature for wearing keffiyeh
MPP Sarah Jama was asked to leave the Legislative Assembly of Ontario by House Speaker Ted Arnott on Thursday for wearing a keffiyeh, a garment that is banned at Queen’s Park.
CTE: Researchers believe widespread brain injury may contribute to veteran suicide rate
Researchers are working to better understand if some Canadian military veterans may be suffering from Chronic Traumatic Encephalopathy, also known as CTE -- a disorder previously found in the brains of professional football and hockey players after their death.
1 arrested in northern Alberta during public shelter order
Residents of John D'Or Prairie, a community on the Little Red River Cree Nation in northern Alberta, were told to take shelter Thursday morning during a police operation.
Secret $70M Lotto Max winners break their silence
During a special winner celebration near their hometown, Doug and Enid shared the story of how they discovered they were holding a Lotto Max ticket worth $70 million and how they kept this huge secret for so long.
Remains from a mother-daughter cold case were found nearly 24 years later, after a deathbed confession from the suspect
A West Virginia father is getting some sense of closure after authorities found the remains of his young daughter and her mother following a deathbed confession from the man believed to have fatally shot them nearly two decades ago.
New deep-water channel allows first ship to pass Key bridge wreckage in Baltimore
The first cargo ship passed through a newly opened deep-water channel in Baltimore on Thursday after being stuck in the harbor since the Francis Scott Key Bridge collapsed four weeks ago, halting most maritime traffic through the city's port.
First in Canada procedure performed at London, Ont. hospital
A London man has become the first person in Canada to receive a robotic assisted surgery on his spine. Dave Myeh suffered from debilitating, chronic back pain that led to sciatica in his right now and extreme pain in his lower back.